Ameriprise Financial Inc. Buys 5,148 Shares of Inogen, Inc. (NASDAQ:INGN)

Ameriprise Financial Inc. raised its holdings in Inogen, Inc. (NASDAQ:INGN) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 848,980 shares of the medical technology company’s stock after acquiring an additional 5,148 shares during the period. Ameriprise Financial Inc.’s holdings in Inogen were worth $7,785,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in shares of Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after acquiring an additional 123,208 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Inogen by 17.9% in the 4th quarter. Renaissance Technologies LLC now owns 492,900 shares of the medical technology company’s stock valued at $4,520,000 after acquiring an additional 75,000 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Inogen by 16.8% in the 4th quarter. Federated Hermes Inc. now owns 404,273 shares of the medical technology company’s stock valued at $3,707,000 after acquiring an additional 58,257 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Inogen by 141.5% in the 4th quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company’s stock valued at $3,301,000 after acquiring an additional 210,961 shares in the last quarter. Finally, Royce & Associates LP raised its holdings in shares of Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock valued at $2,854,000 after acquiring an additional 259,308 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Stifel Nicolaus lowered their price target on Inogen from $10.00 to $7.00 and set a “hold” rating on the stock in a report on Thursday, May 8th. StockNews.com cut Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, April 9th.

Inogen Trading Down 4.9%

Shares of NASDAQ INGN opened at $5.96 on Thursday. The stock has a market cap of $160.25 million, a price-to-earnings ratio of -2.65 and a beta of 1.63. Inogen, Inc. has a 1-year low of $5.70 and a 1-year high of $13.33. The stock’s 50-day moving average is $6.90 and its 200 day moving average is $8.74.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.27. The company had revenue of $82.28 million for the quarter, compared to analysts’ expectations of $79.57 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. On average, analysts forecast that Inogen, Inc. will post -1.73 EPS for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.